[HTML][HTML] Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology …

A Tyndall, UA Walker, A Cope, F Dazzi… - Arthritis research & …, 2007 - Springer
Multipotent mesenchymal stromal cells isolated from bone marrow and other sites are
currently being studied to determine their potential role in the pathogenesis and/or …

Respiratory chain encephalomyopathies: a diagnostic classification

UA Walker, S Collins, E Byrne - European neurology, 1996 - karger.com
Mitochondrial encephalomyopathies are a heterogenous group of disorders with various
biochemical defects of the respiratory chain (RC). Due to the considerable phenotypic …

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

F Van Den Hoogen, D Khanna, J Fransen… - Arthritis & …, 2013 - Wiley Online Library
Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The …

Role of mtDNA lesions in anthracycline cardiotoxicity

D Lebrecht, UA Walker - Cardiovascular toxicology, 2007 - Springer
Doxorubicin (adriamycin) is an effective drug in the treatment of many malignancies. Its
prolonged use is, however, limited by an irreversible, dose-dependent and progressive …

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

AJ Tyndall, B Bannert, M Vonk, P Airò… - Annals of the …, 2010 - ard.bmj.com
Objectives To determine the causes and predictors of mortality in systemic sclerosis (SSc).
Methods Patients with SSc (n= 5860) fulfilling the American College of Rheumatology …

Update of EULAR recommendations for the treatment of systemic sclerosis

O Kowal-Bielecka, J Fransen, J Avouac… - Annals of the …, 2017 - ard.bmj.com
The aim was to update the 2009 European League against Rheumatism (EULAR)
recommendations for the treatment of systemic sclerosis (SSc), with attention to new …

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

D Khanna, CJF Lin, DE Furst, J Goldin… - The Lancet …, 2020 - thelancet.com
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

F Hoogen, D Khanna, J Fransen, SR Johnson, M Baron… - 2013 - deepblue.lib.umich.edu
Objective. The 1980 American College of Rheuma-tology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The …

Mapping and predicting mortality from systemic sclerosis

M Elhai, C Meune, M Boubaya, J Avouac… - Annals of the …, 2017 - ard.bmj.com
Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc).
Methods Between 2000 and 2011, we examined the death certificates of all French patients …

[HTML][HTML] Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility

C Sur Chowdhury, S Giaglis, UA Walker… - Arthritis research & …, 2014 - Springer
Abstract Introduction Neutrophil extracellular traps (NETs) have recently been implicated in
a number of autoimmune conditions, including rheumatoid arthritis (RA). We examined the …